Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Jingjie Li
 -- 1973 2024-01-02 09:22:57 |
2 references update
Fanny Huang
 Meta information modification 1973 2024-01-02 10:21:43 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wang, W.; Wang, H.; Long, Y.; Li, Z.; Li, J. Drug Treatments for Hair Loss. Encyclopedia. Available online: https://encyclopedia.pub/entry/53311 (accessed on 17 May 2024).
Wang W, Wang H, Long Y, Li Z, Li J. Drug Treatments for Hair Loss. Encyclopedia. Available at: https://encyclopedia.pub/entry/53311. Accessed May 17, 2024.
Wang, Wuji, Honglan Wang, Yunluan Long, Zheng Li, Jingjie Li. "Drug Treatments for Hair Loss" Encyclopedia, https://encyclopedia.pub/entry/53311 (accessed May 17, 2024).
Wang, W., Wang, H., Long, Y., Li, Z., & Li, J. (2024, January 02). Drug Treatments for Hair Loss. In Encyclopedia. https://encyclopedia.pub/entry/53311
Wang, Wuji, et al. "Drug Treatments for Hair Loss." Encyclopedia. Web. 02 January, 2024.
Drug Treatments for Hair Loss
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biom14010020

Apoptosis is a physiological process that occurs in all cell types of the human body, and it profoundly changes the fate of hair by affecting hair follicle cells. Apoptosis induces cellular changes and exhibits distinctive properties through intricate signaling pathways. Hair follicles undergo cyclic periods of growth, regression, and dormancy. Apoptosis is closely correlated with the regression phase by triggering hair follicle cell death and shedding. Regulation of apoptosis in hair follicles plays an essential role in hair loss due to maladies and drug treatments. Mitigating apoptosis can enhance hair growth and minimize hair loss. 

apoptosis hair follicles molecular mechanisms hair loss medicine treatment

1. Introduction

Apoptosis refers to the programmed cell death that influences various biological processes. During early development, apoptosis facilitates the removal of excess cells to ensure normal development, such as the gradual disappearance of the tadpole tail and the development of human fingers from a duck-like webbed foot [1]. After maturation, apoptosis remains an important part of metabolism and is responsible for the removal of damaged and dysfunctional cells or organelles. Thus, the cells in an organism are in a state of dynamic equilibrium that maintains homeostasis and normal function.
The regulation of apoptosis primarily involves the mitochondrial and death receptor pathways; however, new evidence suggests the involvement of the endoplasmic reticulum (ER) in regulating apoptosis [2]. Exposure to external stimuli can trigger endoplasmic reticulum stress (ERS) potentially caused by the accumulation of unfolded or misfolded proteins in the ER lumen [3]. ERS-induced apoptosis is primarily mediated by four major pathways, namely PERK, IRE1α [4], ATF6, and Ca2+, which involve oxidative stress, the activation of AKT and JNK, and the direct activation of caspase-12 [5], ultimately inducing apoptosis.
The hair follicle is a unique mammalian skin structure that plays an indispensable role in skin function and regeneration as one of the important skin appendages. The hair follicle is a microscopic organ with an extremely high capacity for self-renewal and cycling through multiple hair cycles. The hair anatomy comprises, from top to bottom, the infundibulum, isthmus, bulge region, and hair bulb, and if described simply from the inside–out, the hair shaft, inner root sheath, outer root sheath, and connective tissue sheath are included in the dermal sheath (DS) [6].
Hair loss is prevalent worldwide, with chemotherapy-induced alopecia (CIA) being the most common. Although the mechanisms underlying hair loss are not yet entirely understood, apoptosis has been implicated in the pathogenesis of hair loss, particularly in CIA. However, the association between apoptosis and other forms of hair loss, such as alopecia areata (AA), lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and androgenetic alopecia (AGA), remains unclear.

2. Drug Treatments for Hair Loss: Targeting Apoptosis and Signaling Pathways

Alopecia is classified into either cicatricial or non-cicatricial. Cicatricial alopecia includes AGA, chemotherapy-induced alopecia areata, and telogen effluvium, while non-cicatricial alopecia includes lichen planopiloaris, frontal fibrosing alopecia, and lupus erythematosus [7]. Both classes are closely associated with apoptosis of hair follicle cells, most of which correlate with apoptosis of HFSCs. However, in some specific cases of hair loss, multiple factors are involved, such as genetics and the hair follicle microenvironment [8][9][10][11][12].

2.1. Androgenetic Alopecia

Androgenetic alopecia (AGA), the most common type of alopecia, is a heritable disease characterized by androgen dependence and a combination of factors in which hair follicles are progressively miniaturized by androgen, leading to hair reduction and thinning, which can occur in males and females [12][13]. Deng [14] has previously shown that the androgen receptor (AR) in DP cells mediated the paracrine secretion of TGF-β signaling and induced apoptosis of microvascular endothelial cells, thus making it difficult for hair follicles to enter the anagen phase. Xie et al. [15] showed that androgenetic alopecia-induced shrinkage or loss of the hair shaft caused mechanical compression, while the activation of Piezo1 channels triggered Ca2+ inward flow, thereby increasing TNF-α sensitivity and inducing long-term apoptosis in HFSCs.
P53 expression is significantly increased in the hair follicles of the frontal baldness area in patients with AGA, whereas the expressions of the DNA repair marker proteins APE1, PCNA, and PARP-1 were significantly reduced. This suggests that the DNA repair capacity during AGA is not sufficient to counteract the effects of apoptosis [16]. Conventional treatments for AGA include minoxidil and finasteride. Minoxidil restores hair growth mainly by promoting the microvascular concentration of hair follicles to increase the concentration of growth factors. Finasteride is an inhibitor of 5α-reductase, a key enzyme in the conversion of androgens in vivo, and reduces the conversion of androgenic testosterone to its active form, dihydrotestosterone [17]. Treatment with natural product extracts or monomers has also been used, such as proanthocyanidins, which inhibit hair epithelial cell apoptosis and thus promote hair growth [18]. Ginsenoside F2 reduces hair cells apoptosis by modulating TGF-β2 in DHT-induced AGA mice and HaCaT cell models [19]. Baicalin and linoleic acid reduce hair cell apoptosis by regulating IGF-1 [20][21], while forsythiaside-A, which inhibits hair cell apoptosis by decreasing the expression of caspases-9 and -3 and TGF-β2, delays the entry into the catagen phase [22].

2.2. Alopecia Areata

Alopecia areata (AA) is characterized by common non-scarring alopecia due to autoimmune disorders. Collapse of the immune privilege (IP) of the hair follicle bulb is an important driver of baldness, manifested by lymphocyte infiltration around the hair follicle during the anagen phase [23]. In immune therapy, drugs such as diphencyprone are used to reduce the aggregation of immune cells around the hair follicles [24]. By acting as allergens, diphencyprone induces a localized immune response in small areas of the scalp, away from the follicular region. Local subcutaneous injections of steroids are also used in treatment, along with emerging therapies like Janus kinase (JAK) inhibitors that directly inhibit downstream effectors of the immune response [25]. Additionally, the use of diphencyprone slightly increased the expression of apoptosis inhibitors p16 and survivin in AA patients [26], and Bcl-2 expression was significantly increased in recovered AA patients’ scalps [27].
However, there is also a strong genetic association with the development of AA, with significant alterations in the apoptosis/autophagy pathway [28]. In a case–control analysis, FAS and FASLG gene polymorphisms affected the risk of developing AA; that is, mutations in FAS and FASLG may be a cause of AA [29]. FAS and FASL-deficient mice are resistant to the development of AA, and AA mice showed more FASL-positive cells than control mice, possibly due to increased FASL gene expression during AA, which caused apoptosis of hair follicle cells [30].

2.3. Chemotherapy-Induced Alopecia

Chemotherapy-induced alopecia (CIA) is a common adverse effect in patients receiving chemotherapy and manifests as patchy or diffuse anagen alopecia that may progress to complete hair loss within 2–3 months [31]. There are two forms of damage attributed to CIA: One is the dystrophic anagen phase, in which hairs are stimulated by low doses of chemotherapeutic drugs, manifesting in an outgrowth of the hair shaft and damage to the structure of the hair follicle, which returns to the second cycle, during which hair loss is rare. The other is the dystrophic catagen phase, which refers to the destruction of the hair follicle structure after receiving high doses of chemotherapeutic drugs, characterized by the fragmentation of melanocytes, rapid and massive hair loss, and a rapid subsequent growth cycle within a short period of time [32].
A common clinical treatment option is scalp cooling to reduce drug damage to hair follicles by reducing the uptake and metabolism of local chemotherapeutic drugs. The active metabolite of CYP, 4-hydroperoxycyclophosphamide 4-HC, causes DNA damage and apoptosis, while PPAR-γ agonist NAGED pretreatment prevented 4-HC-induced apoptosis in human eHFSCs [33]. Some herbal extracts also have good therapeutic effects on CIA. Ginseng is commonly applied in the treatment of hair loss; for example, Korean red ginseng extract (KRGE) can prevent 4-HC-induced follicular anagen inhibition and premature catagen by reducing P53 and Bax/Bcl2 expression. KRGE also alleviates 4-HC-induced proliferation inhibition and apoptosis in matrix keratinocyte cells [34]. Monomeric compounds from Chinese herbal medicine also have good prospects for development, such as the decursin in Angelica, which can reduce the expression of PI3K/AKT signaling and MAPK signaling pathways in TNF-α-stimulated keratinocytes. Decursin has also been shown to reduce the expression of apoptosis-related factors and caspase family, while increasing the expression of epidermal growth factor, with certain therapeutic effects against CIA [35].

2.4. Primary Lymphocytic Cicatricial Alopecia

Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are primary lymphocytic cicatricial hair loss disorders. Similar to AA, hair follicles attacked by CD8+ cells due to the loss of IP at the bundle site undergo apoptosis and pathological epithelial-to-mesenchymal transition (EMT) of stem cells, and eventually loss of the regenerative capacity of the hair follicles [36]. HFSCs within the bulge are depleted, which is reflected in the tissue examination of the scalp of patients with LPP, where HFSCs showed an increase in apoptosis [37]. In contrast, FFA is more oriented toward pathological EMT and hair fibrosis [38].
Therefore, the most direct route to treat LPP and FFA is to inhibit IP collapse and reduce HFSC apoptosis with drugs such as tacrolimus that inhibits IP collapse in the bulb in vitro [39] and has undergone clinical trials [40]. In addition, agonists of the PPAR-γ pathway can partially reverse EMT at the bulb and are effective in isolated LPP hair follicles [41] and protect K15+ eHFSCs in the bulge region of LPP hair follicles from apoptotic injury, while reducing the number of CD8+ cells and MHCII+ cells among them [42].
Currently, various pharmaceutical interventions are being investigated to treat these diseases. Drugs that specifically target and regulate apoptosis can be classified into natural remedies and extracts, chemically synthesized, or biologically prepared (Table 1).
Table 1. Pharmaceutical interventions and regulatory factors.
Classification Ingredient Study Model Effect Mechanism Reference
AA Diphencyprone Human skin Increased microvessels ↑P16, ↑survivin [26]
AA Diphenylcyclopropenone C57BL/6 mice,
Human skin		 Autoreactive T cell activation induced cell death ↑FasL [43]
AA Diphencyprone Human skin Hair growth improved ↑Bcl-2 [27]
AA Tofacitinib citrate delivered phospholipid calcium carbonate hybrid nanoparticles C57BL/6 mice Apoptosis restrained in CYP-induced follicles cells, AA relieved - [44]
AGA Caizhixuan hair tonic C57BL/6 mice Hair regrowth improved ↓Caspase-3, Bax; ↑Bcl-2 [45]
AGA Policosanol KM mice, Human follicle dermal papilla cells (HFDPCS) HFDPCS apoptosis increased ↓TGF-β2, cleaved caspase-9, cleaved caspase-3, Bax; ↑Bcl-2 [46]
AGA Ginsenoside F2 HFDPCS, HaCaT cells, C57BL/6 mice HFDPCS and HaCaT cell proliferation increased, hair cell apoptosis and premature entry to catagen suppressed ↓TGF-β2, cleaved caspase-3, Bax, caspase-12; ↑Bcl-2 [19]
AGA Forsythiaside-A HFDPCS, HaCaT cells, C57BL/6 mice Mouse hair density and thickness increased, HFDPCS and HaCaT cells apoptosis suppressed ↓TGF-β2, caspase-9, caspase-3, Bax; ↑Bcl-2 [22]
AGA Stauntonia hexaphylla Extract C57BL/6 mice, HFDPCS Inhibited 5α-reductase and AR resulting in reduced apoptosis and induced cell proliferation in HFDPCS ↓Bax/Bcl-2; ↑PARP-1 [47]
AGA Finasteride-loaded microspheres C57BL/6 mice Finasteride-loaded microspheres for subcutaneous use significantly reduced testosterone-induced alopecia ↓TGF-β2, caspase-3 [48]
AGA Acanthus ebracteatus Vahl. extract and verbascoside HFDPCS, RAW 264.7 cells Inhibited the release of pro-inflammatory cytokines from RAW 264.7 cells and HFDPCS prevented cell apoptosis induced by testosterone ↓TNF-α [49]
AGA Phospholipid–polymer hybrid nanoparticle-mediated transfollicular delivery of quercetin SD rats Hair regrowth potential improved, HFs cell apoptosis inhibited - [50]
AGA Triton-modified polyethyleneimine conjugates assembled with growth arrest-specific protein 6 C57BL/6 mice Transfected Gas6 prolongs the anagen status, inhibited hair follicle cell apoptosis ↑Bcl-2 [51]
AGA VEGF HFSCS Reversed the 5α-DHT-induced apoptosis of HFSCS ↑Bcl-2/Bax; ↓caspase-3 [52]
AGA Sulforaphane, glucosinlates, Brassica oleracea L. var. italica Planch extract HaCaT cells, DPC Enhanced DPC and HaCaT cells viability ↓Bax [53]
CIA Decursin C57BL/6 mice, HaCaT cells Recovered dystrophic hair follicles, hair regeneration restoration ↓Caspases -3, -7, and -8 [35]
CIA N-acetyl-GED-0507-34-Levo Human hair follicle Reduced eHFSC DNA damage and EMT ↓P53 [33]
CIA α-lipoic acid derivative C57BL/6 mice Decreased vascular endothelial cell apoptosis, enhanced vascular permeability ↑IGF-1 [54]
CIA Palbociclib Human hair follicle Suppressed hair matrix keratinocyte apoptosis induced by stem cell injury ↓Caspase-3 [55]
CIA YH0618 C57BL/6 mice Inhibited alopecia ↓Bax/Bcl-2 [56]
CIA Human placenta C57BL/6 mice Increased Ki67-positive cells in hair follicles ↑Bcl-2/Bax; ↓P53, Cyt c, caspases-3 and -9 [57]
CIA Shh protein C57BL/6 mice, human skin Shh protein partially rescued hair loss ↓caspase-3 [58]

References

  1. Fuchs, Y.; Steller, H. Programmed cell death in animal development and disease. Cell 2011, 147, 742–758.
  2. Zhang, J.; Guo, J.; Yang, N.; Huang, Y.; Hu, T.; Rao, C. Endoplasmic reticulum stress-mediated cell death in liver injury. Cell Death Dis. 2022, 13, 1051.
  3. Tabas, I.; Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 2011, 13, 184–190.
  4. Siwecka, N.; Rozpedek-Kaminska, W.; Wawrzynkiewicz, A.; Pytel, D.; Diehl, J.A.; Majsterek, I. The Structure, Activation and Signaling of IRE1 and Its Role in Determining Cell Fate. Biomedicines 2021, 9, 156.
  5. Mekahli, D.; Bultynck, G.; Parys, J.B.; De Smedt, H.; Missiaen, L. Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb. Perspect. Biol. 2011, 3, a004317.
  6. Schneider, M.R.; Schmidt-Ullrich, R.; Paus, R. The hair follicle as a dynamic miniorgan. Curr. Biol. 2009, 19, R132–R142.
  7. Alessandrini, A.; Bruni, F.; Piraccini, B.M.; Starace, M. Common causes of hair loss—Clinical manifestations, trichoscopy and therapy. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 629–640.
  8. Yuan, A.; Xia, F.; Bian, Q.; Wu, H.; Gu, Y.; Wang, T.; Wang, R.; Huang, L.; Huang, Q.; Rao, Y.; et al. Ceria Nanozyme-Integrated Microneedles Reshape the Perifollicular Microenvironment for Androgenetic Alopecia Treatment. ACS Nano 2021, 15, 13759–13769.
  9. Anzai, A.; Wang, E.H.C.; Lee, E.Y.; Aoki, V.; Christiano, A.M. Pathomechanisms of immune-mediated alopecia. Int. Immunol. 2019, 31, 439–447.
  10. Sagawa, N.; Oshima, Y.; Hiratsuka, T.; Kono, Y.; Etoh, T.; Inomata, M. Role of increased vascular permeability in chemotherapy-induced alopecia: In vivo imaging of the hair follicular microenvironment in mice. Cancer Sci. 2020, 111, 2146–2155.
  11. Lee, T.J.; Kang, H.K.; Berry, J.C.; Joo, H.G.; Park, C.; Miller, M.J.; Choi, K. ER71/ETV2 Promotes Hair Regeneration from Chemotherapeutic Drug-Induced Hair Loss by Enhancing Angiogenesis. Biomol. Ther. 2021, 29, 545–550.
  12. Adil, A.; Godwin, M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017, 77, 136–141.e135.
  13. Starace, M.; Orlando, G.; Alessandrini, A.; Piraccini, B.M. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am. J. Clin. Dermatol. 2020, 21, 69–84.
  14. Deng, Z.; Chen, M.; Liu, F.; Wang, Y.; Xu, S.; Sha, K.; Peng, Q.; Wu, Z.; Xiao, W.; Liu, T.; et al. Androgen Receptor-Mediated Paracrine Signaling Induces Regression of Blood Vessels in the Dermal Papilla in Androgenetic Alopecia. J. Investig. Dermatol. 2022, 142, 2088–2099.e2089.
  15. Xie, Y.; Chen, D.; Jiang, K.; Song, L.; Qian, N.; Du, Y.; Yang, Y.; Wang, F.; Chen, T. Hair shaft miniaturization causes stem cell depletion through mechanosensory signals mediated by a Piezo1-calcium-TNF-alpha axis. Cell Stem Cell 2022, 29, 70–85.e76.
  16. El-Domyati, M.; Attia, S.; Saleh, F.; Bassyouni, M.I.; El-Fakahany, H.; Abdel-Wahab, H. Proliferation, DNA repair and apoptosis in androgenetic alopecia. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 7–12.
  17. Kelly, Y.; Blanco, A.; Tosti, A. Androgenetic Alopecia: An Update of Treatment Options. Drugs 2016, 76, 1349–1364.
  18. Gupta, A.K.; Talukder, M.; Bamimore, M.A. Natural products for male androgenetic alopecia. Dermatol. Ther. 2022, 35, e15323.
  19. Shin, H.S.; Park, S.Y.; Hwang, E.S.; Lee, D.G.; Mavlonov, G.T.; Yi, T.H. Ginsenoside F2 reduces hair loss by controlling apoptosis through the sterol regulatory element-binding protein cleavage activating protein and transforming growth factor-beta pathways in a dihydrotestosterone-induced mouse model. Biol. Pharm. Bull. 2014, 37, 755–763.
  20. Chen, L.; Fan, B.; Gu, H.; Yang, L.; Li, X. Effects of Baicalin on Alopecia and the Associated Mechanism. Biomed. Res. Int. 2022, 2022, 3139123.
  21. Ryu, H.S.; Jeong, J.; Lee, C.M.; Lee, K.S.; Lee, J.N.; Park, S.M.; Lee, Y.M. Activation of Hair Cell Growth Factors by Linoleic Acid in Malva verticillata Seed. Molecules 2021, 26, 2117.
  22. Shin, H.S.; Park, S.Y.; Song, H.G.; Hwang, E.; Lee, D.G.; Yi, T.H. The Androgenic Alopecia Protective Effects of Forsythiaside-A and the Molecular Regulation in a Mouse Model. Phytother. Res. 2015, 29, 870–876.
  23. Zhou, C.; Li, X.; Wang, C.; Zhang, J. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management. Clin. Rev. Allergy Immunol. 2021, 61, 403–423.
  24. Happle, R. Antigenic competition as a therapeutic concept for alopecia areata. Arch. Dermatol. Res. 1980, 267, 109–114.
  25. Pratt, C.H.; King, L.E., Jr.; Messenger, A.G.; Christiano, A.M.; Sundberg, J.P. Alopecia areata. Nat. Rev. Dis. Primers 2017, 3, 17011.
  26. Simonetti, O.; Lucarini, G.; Bernardini, M.L.; Simoncini, C.; Biagini, G.; Offidani, A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: An immunohistochemical study. Br. J. Dermatol. 2004, 150, 940–948.
  27. Pazoki-Toroudi, H.; Ajami, M.; Babakoohi, S.; Khaki, L.; Habibey, R.; Akhiani, M.; Seirafi, H.; Firooz, A. Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata. Immunopharmacol. Immunotoxicol. 2010, 32, 422–425.
  28. Betz, R.C.; Petukhova, L.; Ripke, S.; Huang, H.; Menelaou, A.; Redler, S.; Becker, T.; Heilmann, S.; Yamany, T.; Duvic, M.; et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat. Commun. 2015, 6, 5966.
  29. Fan, X.; Shangguan, L.; Li, M.; Li, C.Y.; Liu, B. Functional polymorphisms of the FAS/FASLG genes are associated with risk of alopecia areata in a Chinese population: A case-control analysis. Br. J. Dermatol. 2010, 163, 340–344.
  30. Freyschmidt-Paul, P.; McElwee, K.J.; Botchkarev, V.; Kissling, S.; Wenzel, E.; Sundberg, J.P.; Happle, R.; Hoffmann, R. Fas-deficient C3.MRL-Tnfrsf6(lpr) mice and Fas ligand-deficient C3H/HeJ-Tnfsf6(gld) mice are relatively resistant to the induction of alopecia areata by grafting of alopecia areata-affected skin from C3H/HeJ mice. J. Investig. Dermatol. Symp. Proc. 2003, 8, 104–108.
  31. Freites-Martinez, A.; Shapiro, J.; Goldfarb, S.; Nangia, J.; Jimenez, J.J.; Paus, R.; Lacouture, M.E. Hair disorders in patients with cancer. J. Am. Acad. Dermatol. 2019, 80, 1179–1196.
  32. Paus, R.; Haslam, I.S.; Sharov, A.A.; Botchkarev, V.A. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013, 14, e50–e59.
  33. Piccini, I.; Brunken, L.; Cheret, J.; Ghatak, S.; Ramot, Y.; Alam, M.; Purba, T.S.; Hardman, J.; Erdmann, H.; Jimenez, F.; et al. Peroxisome proliferator-activated receptor-gamma signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial-mesenchymal transition. Br. J. Dermatol. 2022, 186, 129–141.
  34. Keum, D.I.; Pi, L.Q.; Hwang, S.T.; Lee, W.S. Protective effect of Korean Red Ginseng against chemotherapeutic drug-induced premature catagen development assessed with human hair follicle organ culture model. J. Ginseng Res. 2016, 40, 169–175.
  35. Kim, M.H.; Park, S.J.; Yang, W.M. Network Pharmacology Study and Experimental Confirmation Revealing the Ameliorative Effects of Decursin on Chemotherapy-Induced Alopecia. Pharmaceuticals 2021, 14, 1150.
  36. Senna, M.M.; Peterson, E.; Jozic, I.; Cheret, J.; Paus, R. Frontiers in Lichen Planopilaris and Frontal Fibrosing Alopecia Research: Pathobiology Progress and Translational Horizons. JID Innov. 2022, 2, 100113.
  37. Harries, M.J.; Meyer, K.; Chaudhry, I.; Kloepper, J.K.; Poblet, E.; Griffiths, C.E.; Paus, R. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche. J. Pathol. 2013, 231, 236–247.
  38. Harries, M.J.; Jimenez, F.; Izeta, A.; Hardman, J.; Panicker, S.P.; Poblet, E.; Paus, R. Lichen Planopilaris and Frontal Fibrosing Alopecia as Model Epithelial Stem Cell Diseases. Trends Mol. Med. 2018, 24, 435–448.
  39. Ito, T.; Ito, N.; Bettermann, A.; Tokura, Y.; Takigawa, M.; Paus, R. Collapse and restoration of MHC class-I-dependent immune privilege: Exploiting the human hair follicle as a model. Am. J. Pathol. 2004, 164, 623–634.
  40. Mahmoudi, H.; Rostami, A.; Tavakolpour, S.; Nili, A.; Teimourpour, A.; Salehi Farid, A.; Abedini, R.; Amini, M.; Daneshpazhooh, M. Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: A randomized controlled trial. J. Dermatol. Treat. 2022, 33, 284–290.
  41. Imanishi, H.; Ansell, D.M.; Cheret, J.; Harries, M.; Bertolini, M.; Sepp, N.; Biro, T.; Poblet, E.; Jimenez, F.; Hardman, J.; et al. Epithelial-to-Mesenchymal Stem Cell Transition in a Human Organ: Lessons from Lichen Planopilaris. J. Investig. Dermatol. 2018, 138, 511–519.
  42. Cheret, J.; Piccini, I.; Hardman-Smart, J.; Ghatak, S.; Alam, M.; Lehmann, J.; Jimenez, F.; Erdmann, H.; Poblet, E.; Botchkareva, N.; et al. Preclinical evidence that the PPARgamma modulator, N-Acetyl-GED-0507-34-Levo, may protect human hair follicle epithelial stem cells against lichen planopilaris-associated damage. J. Eur. Acad. Dermatol. Venereol. 2020, 34, e195–e197.
  43. Herbst, V.; Zoller, M.; Kissling, S.; Wenzel, E.; Stutz, N.; Freyschmidt-Paul, P. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur. J. Dermatol. EJD 2006, 16, 537–542.
  44. Guan, Y.; Yan, A.; Qiang, W.; Ruan, R.; Yang, C.; Ma, K.; Sun, H.; Liu, M.; Zhu, H. Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata. Int. J. Mol. Sci. 2023, 24, 8427.
  45. Fang, T.; Xu, R.; Sun, S.; He, Y.; Yan, Y.; Fu, H.; Luo, H.; Cao, Y.; Tao, M. Caizhixuan hair tonic regulates both apoptosis and the PI3K/Akt pathway to treat androgenetic alopecia. PLoS ONE 2023, 18, e0282427.
  46. Wang, Z.D.; Feng, Y.; Sun, L.; Gan, J.; Li, X.; Ding, W.F.; Chen, X.M. Anti-androgenetic alopecia effect of policosanol from Chinese wax by regulating abnormal hormone levels to suppress premature hair follicle entry into the regression phase. Biomed. Pharmacother. 2021, 136, 111241.
  47. Hong, G.L.; Lee, H.J.; Kim, Y.J.; Kim, K.H.; Jung, J.Y. Stauntonia hexaphylla Extract Ameliorates Androgenic Alopecia by Inhibiting Androgen Signaling in Testosterone-induced Alopecia Mice. Iran. J. Pharm. Res. 2022, 21, e133333.
  48. Kim, J.H.; Na, J.; Bak, D.H.; Lee, B.C.; Lee, E.; Choi, M.J.; Ryu, C.H.; Lee, S.; Mun, S.K.; Park, B.C.; et al. Development of finasteride polymer microspheres for systemic application in androgenic alopecia. Int. J. Mol. Med. 2019, 43, 2409–2419.
  49. Wisuitiprot, V.; Ingkaninan, K.; Chakkavittumrong, P.; Wisuitiprot, W.; Neungchamnong, N.; Chantakul, R.; Waranuch, N. Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. Sci. Rep. 2022, 12, 1491.
  50. Das, L.; Kaurav, M.; Pandey, R.S. Phospholipid-polymer hybrid nanoparticle-mediated transfollicular delivery of quercetin: Prospective implement for the treatment of androgenic alopecia. Drug Dev. Ind. Pharm. 2019, 45, 1654–1663.
  51. Fan, X.; Zhao, X.; Xu, J.; Wang, J.; Wang, Q.; Tang, X. Triton modified polyethyleneimine conjugates assembled with growth arrest-specific protein 6 for androgenetic alopecia transdermal gene therapy. Mater. Today Bio 2023, 19, 100575.
  52. Zhang, X.; Zhou, D.; Ma, T.; Liu, Q. Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients with Androgenic Alopecia. Dermatol. Surg. 2020, 46, 358–368.
  53. Luo, Z.; Zhang, X. Brassica oleracea extract, glucosinlates, and sulforaphane promote hair growth in vitro and ex vivo. J. Cosmet. Dermatol. 2022, 21, 1178–1184.
  54. Aiba, T.; Kono, Y.; Etoh, T.; Kawano, Y.; Oshima, Y.; Inomata, M. Efficacy of cooling therapy and alpha-lipoic acid derivative against chemotherapy-induced alopecia in an animal model. Cancer Sci. 2023, 114, 1007–1014.
  55. Purba, T.S.; Ng’andu, K.; Brunken, L.; Smart, E.; Mitchell, E.; Hassan, N.; O’Brien, A.; Mellor, C.; Jackson, J.; Shahmalak, A.; et al. CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia. EMBO Mol. Med. 2019, 11, e11031.
  56. You, J.; Gao, F.; Tang, H.; Peng, F.; Jia, L.; Huang, K.; Chow, K.; Zhao, J.; Liu, H.; Lin, Y.; et al. A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4. J. Cancer 2019, 10, 3665–3677.
  57. Kim, M.H.; Kim, K.; Lee, H.; Yang, W.M. Human placenta induces hair regrowth in chemotherapy-induced alopecia via inhibition of apoptotic factors and proliferation of hair follicles. BMC Complement. Med. Ther. 2020, 20, 230.
  58. Haslam, I.S.; Zhou, G.; Xie, G.; Teng, X.; Ao, X.; Yan, Z.; Smart, E.; Rutkowski, D.; Wierzbicka, J.; Zhou, Y.; et al. Inhibition of Shh Signaling through MAPK Activation Controls Chemotherapy-Induced Alopecia. J. Investig. Dermatol. 2021, 141, 334–344.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Dermatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Wuji Wang
,
Honglan Wang
,
Yunluan Long
,
Zheng Li
,
Jingjie Li
View Times: 147
Revisions: 2 times (View History)
Update Date: 02 Jan 2024
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback